Close Menu

NEW YORK – Thermo Fisher Scientific and Owlstone Medical said on Thursday that they have entered into a collaborative partnership to advance the early diagnosis of cancer and other diseases through the discovery and validation of biomarkers by noninvasive breath sampling.

Thermo Fisher said that the initiative will seek to qualify its mass analyzers for the detection of new biomarkers by integrating its Q Exactive GC Hybrid Quadrupole-Orbitrap, a gas chromatography mass spectrometer (GC-MS), into Owlstone Medical's Breath Biopsy platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.